Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13548372 | 0.84 | ALDH1A1 (0.52) | ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL3524028 | 0.81 | BRD9 (0.48) | ALDH1A1KMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL3527781 | 0.79 | HTT (0.46) | ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL3524171 | 0.77 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3523275 | 0.76 | KCNH2 (0.47) | ALDH1A1SMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL7689517 | 0.74 | SMN1; SMN2 (0.51) | ALDH1A1MAPTKMT2AGAAMEN1 | |
| SCHEMBL3524981 | 0.73 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EHSD17B10CYP19A1 | |
| SCHEMBL7002658 | 0.72 | KDM4E (0.46) | ALDH1A1SMN1; SMN2KDM4EJAK2JAK3 | |
| SCHEMBL18392739 | 0.67 | CYP3A4 (0.52) | ALDH1A1MAPTKMT2AGAAMEN1 | |
| SCHEMBL3186208 | 0.67 | CYP3A4 (0.58) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652006-B2 | For therapy and prophylaxis of neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, for ameliorating neurodegenerative diseases | EURO-CELTIQUE S.A. (LU) | 2010-01-26 | — | — | US | claimed |
| US-20040162299-A1 | Substituted quinazolines and analogs and the use thereof | EURO-CELTIQUE, S.A. | 2004-08-19 | — | — | US | claimed |
| EP-1066039-A4 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | COCENSYS INC (US) | 2003-02-26 | — | — | EP | claimed |
| US-20030033089-A1 | Substituted quinazolines and analogs and the use thereof | EURO-CELTIQUE S.A. | 2003-02-13 | — | — | US | claimed |
| EP-1066039-A1 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | Cocensys, Inc. (US) | 2001-01-10 | — | — | EP | claimed |
| WO-1999044612-A1 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | COCENSYS, INC. (US) | 1999-09-10 | — | — | WO | claimed |
| US-7652006-B2 | For therapy and prophylaxis of neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, for ameliorating neurodegenerative diseases | EURO-CELTIQUE S.A. (LU) | 2010-01-26 | — | — | US | disclosed |
| US-20040162299-A1 | Substituted quinazolines and analogs and the use thereof | EURO-CELTIQUE, S.A. | 2004-08-19 | — | — | US | disclosed |
| US-6765006-B2 | ANTAGONISTS OF AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID (AMPA) IONOTROPIC RECEPTORS; NEURODEGENERATIVE, ALZHEIMER'S, AND HUNTINGTON'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; SCHIZOPHRENIA, EXCITATORY AMINO ACID DEFICIENCY | EURO-CELTIQUE S.A. (LU) | 2004-07-20 | — | — | US | disclosed |
| EP-1066039-A4 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | COCENSYS INC (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20030033089-A1 | Substituted quinazolines and analogs and the use thereof | EURO-CELTIQUE S.A. | 2003-02-13 | — | — | US | disclosed |
| US-6465472-B1 | SUCH AS 1-(2-DIETHYLAMINOETHYL)-6,7-METHYLENEDIOXY-4-(3,4-METHYLENE -DIOXYPHENYL)QUINAZOLIN-2(1H)-ONE; AMPA IONOTROPIC RECEPTOR ANTAGONISTS; ANTICONVULSANTS, COGNITIVE ENHANCERS, PREVENTION OF NEURODEGENERATION | EURO-CELTIQUE S.A. (LU) | 2002-10-15 | — | — | US | disclosed |
| EP-1066039-A1 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | Cocensys, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999044612-A1 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | COCENSYS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162299-A1 | Substituted quinazolines and analogs and the use thereof | CHRNA7, CHRNA2, CHRNA10 | ALDH1A1 1819/4885MAPT 170/4885KMT2A 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.